KNOWLEDGE BANK

Interviews

Accelovance China

President
Asia has had a dramatic spike in interest for medical research pharma advancement and global investment China and India are emerging as leaders in clinical trials They recruit patients faster cheaper and are better than Europe South America or the US because the economies are encouraging more research

Articles

Impact Assessment of US Tariff Threat on Indian Healthcare Export

The ongoing tariff fusillades and retorts by the economies like China have precipitated several conundrums and made the trade future nebulous The flat per cent of reciprocal tariff across the sectors include the medical device also The pharmaceutical sector has been kept exempted The current tariff of the Indian drug to the US is zero while the tariffs on US medicines by India is per cent per c...

Research Insights

Persistence of SARS-CoV-2 total Immunoglobulins in a series of Convalescent Plasma and Blood Donors

The vast majority of COVID cases both symptomatic and asymptomatic develop immunity after COVID contagion Whether lasting differences exist between infection and vaccination boosted immunity is yet to be known The aim of this study was to determine how long total antiSARSCoV antibodies due to past infection persist in peripheral blood

Case Studies

Novel Vaccines - Heat Stable Anthrax Vaccine

Challenge Existing approved Anthrax vaccines are based on cellfree filtrates of disintegrated cells of Bacillus anthracis adsorbed onto an aluminiumhydrogel adjuvant A number of side effects are attributed to these vaccines including poor safety profile and a low immunogenicity necessitating repea

Techno Trends

Nuvalent Discovered Novel NVL-520 for the Treatment of Non-Small Cell Lung Cancer

Nuvalent has developed NVL a new treatment for patients with ROSpositive metastatic nonsmall cell lung cancer who have previously undergone treatment with two or more ROS tyrosine kinase inhibitors

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Unlocking New Avenues in Cancer Therapy by Targeting Ubiquitin-Specific Proteases

Dr. Oon Chern Ein

Associate Professor Dr. Oon Chern Ein is dedicated to advancing innovative cancer therapies. She earned her BSc (First Class Hons) in Biotechnology from Universiti Kebangsaan Malaysia and pursued her DPhil in Medical Oncology at the University of Oxford, United Kingdom. Following this, she trained as a postdoctoral fellow at Karolinska Institutet, Sweden. She has served as a lecturer at Universiti Sains Malaysia since 2013. Chern’s work in molecular therapeutics has earned her numerous prestigious awards, including the L’Oreal-UNESCO For Women in Science National Fellowship (2015), the Women of the Future Awards (South East Asia), and the Malaysian National Young Scientist Award (2018). She was further recognized with the Promising Academician Award and Excellent Service Award by the Malaysian Ministry of Higher Education (2019), alongside the British Council Study UK Alumni Award (Professional Achievement Category) and MINDS Women Scientist Award in 2020. Most recently, she received the Singapore Academies-ASEAN Fellowship from the Singapore National Research Foundation to train in drug discovery at A*STAR Singapore to strengthen her industrial insights. Her multidisciplinary research encompasses drug discovery, cancer-targeted therapies, and bioengineering solutions through collaborations with industry partners. She holds two granted patents in Malaysia (MY-203445-A, MY-199524-A) for small molecule inhibitors targeting anti-cancer and anti-angiogenesis pathways. As a member of the Global Young Academy, Chern actively champions female empowerment and education for all. Chern’s research continues to bridge academia and industry, striving to transform cancer therapy through novel therapeutic strategies.

2

Pharma Firms Must Come Together, Ensure Access to Antibiotics in Poor Countries to Take on Superbugs

Saransh Chaudhary

Entrusted with the mandate of augmenting and monetising the company’s intellectual property wealth and driving key tactical initiatives, Saransh Chaudhary joined Venus Remedies in 2016 as Strategic Board Advisor after completing his undergraduate degree in Accounting & Finance from Cass Business School, London. Two years later, he assumed charge as President of the company’s Global Critical Care division and CEO of Venus Medicine Research Centre (VMRC), its R&D wing. In these roles, he translates priorities into actionable strategies.

3

The Regulatory Landscape for Nutraceuticals

Suresh Garg

Suresh Garg is the CMD and Founder of Zeon Life Sciences. He has over 30 years of extensive experience in the fields of nutrition, dairy products, healthcare, and nutraceuticals. Under his leadership, Zeon has become a pioneer in contract manufacturing for nutraceuticals and herbal goods. Owing to his passion and ability to thrive in a variety of sociocultural environments, Zeon has entered international markets.

 

4

Navigating Regulatory Frameworks: “Generic Approvals in Latin America’s Two Giants- Brazil & Mexico

Bhavya Sridevi Sundaraneedi

Sundaraneedi Bhavya Sridevi is a Master’s student of Regulatory Affairs at National Institute of Pharmaceutical Education and Research (NIPER- Raebareli). She had a six-month internship experience at Hetero Labs in Regulatory affairs of Latin America. Her interests include global regulatory affairs and Latin American emerging market regulations.

Dr. Rahul Shukla

Dr. Rahul Shukla, Assistant Professor at the Department of Pharmaceutics, NIPER Raebareli, Lucknow, an Institute of National Importance, under the Ministry of Chemicals & Fertilizers, Govt. of India. He was awarded SERB International Research Experience (SIRE) Fellow. Listed in Stanford University's Top 2% Scientists in Pharmaceutical Sciences Worldwide. 
Research Interest: Pharmaceutics, Nanomedicine, Particle Engineering, Bionanomaterials for various therapeutic applications.
 

5

Why Tackling Antibiotic Tolerance Is Crucial to Combating AMR and Saving Our Existing Antibiotics

Saransh Chaudhary

Entrusted with the mandate of augmenting and monetising the company’s intellectual property wealth and driving key tactical initiatives, Saransh Chaudhary joined Venus Remedies in 2016 as Strategic Board Advisor after completing his undergraduate degree in Accounting & Finance from Cass Business School, London. Two years later, he assumed charge as President of the company’s Global Critical Care division and CEO of Venus Medicine Research Centre (VMRC), its R&D wing. In these roles, he translates priorities into actionable strategies.

press releasesRead more...

Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery

As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company

Collaboration aims to accelerate development of next generation medicines

The Personalised Medicine Centre PMC a joint initiative between Murdoch University and the Perron Institute biotechnology company Syngenis Labs and the Perron Institute are collaborating to establish a specialised preclinical safety testing platform for RNAbased medicines designed to treat diseases...

ITM and AtomVie Global Radiopharma Enter Supply Agreement for n.c.a. Lutetium-177

ITM Isotope Technologies Munich SE ITM a leading radiopharmaceutical biotech company and AtomVie Global Radiopharma AtomVie a radiopharmaceutical contract development and manufacturing organization CDMO today announced a supply agreement

Evotec and Bristol Myers Squibb advance strategic protein degradation partnership with second IND acceptance

Evotec SE NASDAQ EVO Frankfurt Prime Standard EVT today announced that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug IND acceptance from the US Food

Introducing Cognizant® Patient Hub Operations: AI-enabled patient access offering designed to shorten the path from prescription to therapy

Cognizant Nasdaq CTSH today introduced Cognizant Patient Hub Operations an offering built on NVIDIA accelerated computing that pairs AI agents with healthcareexperienced specialists to support patients and help drive better access to therapy

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

Thermo Fisher Scientific the world leader in serving science today announced the Gibco VaxEvo CD Medium a chemically defined and animal originfree medium designed to support suspension HEK cell growth and hightiter adenovirus production

EventsRead more...

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

03 - 04

Dec 2026

LATEST NEWSRead more...

Bionsight Enters into Collaboration with Astellas to Develop Autoimmune Disorder Therapy

Bionsight has entered into a global research and development RD collaboration with Astellas Pharma to explore a potential firstinclass treatment for autoimmune disorders

Isomorphic Labs Enters into Collaboration with MSD for Cancer Drug Discovery

Isomorphic Labs has entered into a strategic research collaboration with MSD to discover smallmolecule drug candidates for an important oncology target

Sanofi Receives Approval for Infilbray to Treat Neurological Symptoms of Type 3 Gaucher Disease

Sanofi has received approval from the US Food and Drug Administration FDA for Infilbray venglustat an oral medicine for treating neurological manifestations of Type Gaucher disease GD in adults and children weighing at least kg

Pfizer Enters into Agreement with Starna Therapeutics for Autoimmune Disease Treatments

Pfizer has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop RNAbased in vivo chimeric antigen receptor Tcell CART therapies for autoimmune diseases

OXB Partners with Aura Biosciences for Drug Manufacturing

OXB has confirmed a manufacturing and supply partnership with Aura Biosciences

GSK Receives Approval for Nelkarmi to Treat Advanced ALK-Positive Lung Cancer

GSK plc LSENYSE GSK has received accelerated approval from the US Food and Drug Administration FDA for Nelkarmi neladalkib a treatment for adults with locally advanced or metastatic anaplastic lymphoma kinase ALKpositive nonsmall cell lung cancer NSCLC